MR Quality + Diagnostic Performance for CHC Diagnosis - Gadoxetic Acid, Gadoteric Acid and P03277 Comparison

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04652947

Enrollment

Registered

2020-12-03

Start date

2016-12-07

Completion date

2017-10-26

Last updated

2020-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

Compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules less than 3 cm, using LIRADS criteria

Interventions

DIAGNOSTIC_TESTMRI diagnostic

no intervention, patient only have MRI

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who had all three MRI scans as part of the diagnosis of the same suspected CHC lesion(s) * Reference diagnosis obtained for suspected CHC nodules by a diagnostic algorithm taking into account histology, imaging and follow-up

Exclusion criteria

* Delay between first MRI and 3rd MRI greater than 3 months

Design outcomes

Primary

Measure	Time frame	Description
compare diagnostic MRI performance of gadoteric acid, gadoxetic acid and P03277 for suspected CHC nodules	3 months	the evaluation criteria will be the classification of each nodule according to the LiRADS citeria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026